Kolexia
Raoul Jean-Luc Gastro-entérologie
Raoul Jean-Luc
Gastro-entérologie
Institut de cancérologie de l'Ouest
Saint-Herblain, France
283 Activités
3 Followers
Scientifique
Digital
Production scientifique
Activités par an
Expertise
Sujets de recherche
{{person.topmesh1.name}} Carcinomes Carcinome hépatocellulaire Tumeurs du foie Métastase tumorale Adénocarcinome Tumeurs du pancréas Tumeurs colorectales Tumeurs neuroendocrines Tumeurs de l'oesophage

Collaborateurs

Voir plus
Gilabert Marine
Gilabert Marine
Centre Paoli-Calmettes, Marseille, France
Edeline Julien
Edeline Julien
Centre Eugène Marquis, Rennes, France
Adhoute Xavier
Adhoute Xavier
Cabinet libéral, Marseille, France
Poizat Flora
Poizat Flora
Centre Paoli-Calmettes, Marseille, France

Industries

Voir plus
Merck-Serono
2 collaboration(s)
Dernière en 2020
Servier
2 collaboration(s)
Dernière en 2021
Transgene
1 collaboration(s)
Dernière en 2020
{{person.topindus4.name}}
{{person.topindus4.tot}} collaboration(s)
Dernière en {{person.topindus4.last}}

Dernières activités

Voir plus
MOST plus: A Two-period, Multicenter, Randomized, Open-label, Phase II Study Evaluating the Clinical Benefit of a Maintenance Treatment Targeting Tumor Molecular Alterations in Patients With Progressive Locally-advanced or Metastatic Solid Tumors
Essai Clinique (Centre Léon-Bérard)   09 février 2024
A Phase II Open Label Study of BMS-582664 in Locally Advanced or Metastatic Hepatocellular Cancer: A Phase II Open Label Study of Brivanib (BMS582664), Administered Orally At A Dose of 800 mg Daily In Subjects With Unresectable, Locally Advanced or Metastatic Hepatocellular Carcinoma Who Have Received Either No Prior Systemic Therapy or One Prior Regimen of Angiogenesis Inhibitor Therapy
Essai Clinique (BMS)   10 novembre 2023
M7824 Monotherapy in Locally Advanced or Metastatic Second Line (2L) Biliary Tract Cancer (Cholangiocarcinoma and Gallbladder Cancer): A Phase II, Multicenter, Open-label Study to Investigate the Clinical Efficacy of M7824 Monotherapy in Participants With Locally Advanced or Metastatic Biliary Tract Cancer Who Fail or Are Intolerant to First-line Platinum-Based Chemotherapy
Essai Clinique (Emd Serono)   24 octobre 2023
COVID-19 Infection despite Previous Vaccination in Cancer Patients and Healthcare Workers: Results from a French Prospective Multicenter Cohort (PAPESCO-19).
Cancers   28 septembre 2023
Esophageal cancer - French intergroup clinical practice guidelines for diagnosis, treatments and follow-up (TNCD, SNFGE, FFCD, GERCOR, UNICANCER, SFCD, SFED, SFRO, ACHBT, SFP, RENAPE, SNFCP, AFEF, SFR).
Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver   25 août 2023
Phase 2 trial of bintrafusp alfa as second-line therapy for patients with locally advanced/metastatic biliary tract cancers.
Hepatology (Baltimore, Md.)   01 avril 2023
Drug-drug interactions with proton pump inhibitors in cancer patients: an underrecognized cause of treatment failure.
ESMO open   08 février 2023
Prolonged response on olaparib maintenance in metastatic pancreatic acinar cell carcinoma associated with a germline BRCA 2 mutation, revealed by severe panniculitis.
Clinical case reports   12 décembre 2022
New Challenges Facing Systemic Therapies of Advanced HCC in the Era of Different First-Line Immunotherapy-Based Combinations.
Cancers   28 novembre 2022
COVID-19 Vaccination Campaign in Cancer Patients and Healthcare Workers-Results from a French Prospective Multicenter Cohort (PAPESCO-19).
Cancers   11 novembre 2022